阅读说明：本技术 针对cd19的人源化抗原结合结构域及其使用方法 (Humanized antigen binding domains against CD19 and methods of use thereof ) 是由 J.J.W.威尔特齐乌斯 S.A.西弗斯 于 2018-04-24 设计创作，主要内容包括：本发明提供了人源化抗CD19抗体或其抗原结合片段,其包含轻链可变(VL)区和重链可变(VH)区,其中人源化VL和VL区衍生自小鼠抗CD19克隆FMC63抗体；人源化VL和/或人源化VH区在框架区中包含一个或多个氨基酸取代。人源化抗CD19抗体或抗原结合片段可以是单链可变片段(scFv)、嵌合抗原受体(CAR)或T细胞受体(TCR)的一部分。本发明的其他方面涉及包含CAR或TCR的细胞及其在T细胞疗法中的用途。(The present invention provides a humanized anti-CD 19 antibody or antigen-binding fragment thereof comprising a light chain Variable (VL) region and a heavy chain Variable (VH) region, wherein the humanized VL and VL regions are derived from a mouse anti-CD 19 cloned FMC63 antibody; the humanized VL and/or humanized VH regions comprise one or more amino acid substitutions in the framework regions. The humanized anti-CD 19 antibody or antigen-binding fragment may be part of a single chain variable fragment (scFv), a Chimeric Antigen Receptor (CAR), or a T Cell Receptor (TCR). Other aspects of the invention relate to cells comprising a CAR or TCR and their use in T cell therapy.)